|Bid||3.2100 x 1000|
|Ask||3.1300 x 1200|
|Day's range||2.9600 - 3.4534|
|52-week range||1.4800 - 5.5900|
|Beta (5Y monthly)||1.71|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The big shareholder groups in Gamida Cell Ltd. ( NASDAQ:GMDA ) have power over the company. Large companies usually...
With the business potentially at an important milestone, we thought we'd take a closer look at Gamida Cell Ltd.'s...
Pfizer's (PFE) ELEVATE UC 52 is the second phase III study on etrasimod for ulcerative colitis to have met primary and key secondary endpoints.